These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 31711450)

  • 61. Adverse drug reactions and outcome of elderly patients on antituberculosis chemotherapy with and without rifampicin.
    Chan CH; Or KK; Cheung W; Woo J
    J Med; 1995; 26(1-2):43-52. PubMed ID: 7561530
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Short- and long-term impacts of azithromycin treatment on the gut microbiota in children: A double-blind, randomized, placebo-controlled trial.
    Wei S; Mortensen MS; Stokholm J; Brejnrod AD; Thorsen J; Rasmussen MA; Trivedi U; Bisgaard H; Sørensen SJ
    EBioMedicine; 2018 Dec; 38():265-272. PubMed ID: 30478001
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study.
    Schnippel K; Berhanu RH; Black A; Firnhaber C; Maitisa N; Evans D; Sinanovic E
    BMC Infect Dis; 2016 Oct; 16(1):593. PubMed ID: 27769174
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The management of tuberculosis: epidemiology, resistance and monitoring.
    Bang D
    Dan Med Bull; 2010 Nov; 57(11):B4213. PubMed ID: 21055374
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Determination of drug susceptibility and DNA fingerprint patterns of clinical isolates of Mycobacterium tuberculosis from Kampala, Uganda.
    Joloba ML; Whalen CC; Cave DM; Eisenach KD; Johnson JL; Okwera A; Morrissey A; Bajaksouzian S; Feagin J; Mugerwa R; Ellner J; Jacobs MR
    East Afr Med J; 2000 Feb; 77(2):111-5. PubMed ID: 10774085
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Drug-resistance of Mycobacterium tuberculosis in Patras, Greece.
    Trakada G; Tsiamita M; Spiropoulos K
    Monaldi Arch Chest Dis; 2004; 61(1):65-70. PubMed ID: 15366340
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: study protocol for a prospective, multicenter, randomized, open-label, phase II trial.
    Lee JY; Kim DK; Lee JK; Yoon HI; Jeong I; Heo E; Park YS; Lee JH; Park SS; Lee SM; Lee CH; Lee J; Choi SM; Park JS; Joh JS; Cho YJ; Lee YJ; Kim SJ; Hwang YR; Kim H; Ki J; Choi H; Han J; Ahn H; Hahn S; Yim JJ
    Trials; 2017 Feb; 18(1):68. PubMed ID: 28193240
    [TBL] [Abstract][Full Text] [Related]  

  • 68. GeneChip analysis of resistant Mycobacterium tuberculosis with previously treated tuberculosis in Changchun.
    Zhang MJ; Ren WZ; Sun XJ; Liu Y; Liu KW; Ji ZH; Gao W; Yuan B
    BMC Infect Dis; 2018 May; 18(1):234. PubMed ID: 29788948
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [CLINICAL EFFECTS OF TREATMENT FOR MYCOBACTERIUM TUBERCULOSIS INFECTION IN PATIENTS AT A SPECIALIZED HOSPITAL IN 2011].
    Okumura M; Sasaki Y; Yoshiyama T; Matsuda S; Osawa T; Morimoto K; Yanai H; Kurasima A; Ogata H; Gotoh H
    Kekkaku; 2015 Oct; 90(10):665-70. PubMed ID: 26821395
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers.
    Kabbani TA; Pallav K; Dowd SE; Villafuerte-Galvez J; Vanga RR; Castillo NE; Hansen J; Dennis M; Leffler DA; Kelly CP
    Gut Microbes; 2017 Jan; 8(1):17-32. PubMed ID: 27973989
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Tuberculosis treatment outcomes among people living with HIV diagnosed using Xpert MTB/RIF versus sputum-smear microscopy in Botswana: a stepped-wedge cluster randomised trial.
    Agizew T; Chihota V; Nyirenda S; Tedla Z; Auld AF; Mathebula U; Mathoma A; Boyd R; Date A; Pals SL; Lekone P; Finlay A
    BMC Infect Dis; 2019 Dec; 19(1):1058. PubMed ID: 31842773
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A prospective longitudinal study on the microbiota composition in amyotrophic lateral sclerosis.
    Di Gioia D; Bozzi Cionci N; Baffoni L; Amoruso A; Pane M; Mogna L; Gaggìa F; Lucenti MA; Bersano E; Cantello R; De Marchi F; Mazzini L
    BMC Med; 2020 Jun; 18(1):153. PubMed ID: 32546239
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Nutrition, Inflammation, and the Gut Microbiota among Outpatients with Active Tuberculosis Disease in India.
    Huey SL; Yu EA; Finkelstein JL; Glesby MJ; Bonam W; Russell DG; Mehta S
    Am J Trop Med Hyg; 2021 Oct; 105(6):1645-1656. PubMed ID: 34662867
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The gut microbiome: A line of defense against tuberculosis development.
    Yu Z; Shen X; Wang A; Hu C; Chen J
    Front Cell Infect Microbiol; 2023; 13():1149679. PubMed ID: 37143744
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 2008 and 2009. A report of the Australian Mycobacterium Reference Laboratory Network.
    Lumb R; Bastion I; Carter R; Jelfs P; Keehner T; Sievers A
    Commun Dis Intell Q Rep; 2011 Jun; 35(2):154-61. PubMed ID: 22010508
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The gut microbiota mediates protective immunity against tuberculosis
    Yang F; Yang Y; Chen L; Zhang Z; Liu L; Zhang C; Mai Q; Chen Y; Chen Z; Lin T; Chen L; Guo H; Zhou L; Shen H; Chen X; Liu L; Zhang G; Liao H; Zeng L; Zeng G
    Gut Microbes; 2022; 14(1):2029997. PubMed ID: 35343370
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Non-Beijing strains of Mycobacterium tuberculosis in China.
    Li X; Xu P; Shen X; Qi L; DeRiemer K; Mei J; Gao Q
    J Clin Microbiol; 2011 Jan; 49(1):392-5. PubMed ID: 21068281
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
    Xia H; van den Hof S; Cobelens F; Zhou Y; Zhao B; Wang S; Zhao Y
    BMC Infect Dis; 2020 Jan; 20(1):19. PubMed ID: 31910878
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients.
    Galloway-Peña JR; Smith DP; Sahasrabhojane P; Wadsworth WD; Fellman BM; Ajami NJ; Shpall EJ; Daver N; Guindani M; Petrosino JF; Kontoyiannis DP; Shelburne SA
    Genome Med; 2017 Feb; 9(1):21. PubMed ID: 28245856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.